In this randomized controlled trial (RCT), the investigators will determine whether a 6-month
course of oral Micronized Purified Flavonoid Fraction (MPFF 1000 mg daily), compared with
placebo, improves the symptoms and signs of the post-thrombotic syndrome (PTS) and quality of
life (QOL) at 6 months follow-up.